SUMMARY Hereditary osteo-onychodysplasia (HOOD, nail-patella syndrome) is an autosomal dominant condition characterised by nail dysplasia, patellar hypoplasia or aplasia, and nephropathy. The risk for HOOD patients to have a child with HOOD who will develop renal failure cannot easily be deduced from published pedigrees. We have studied a large family with 30 patients with HOOD and have analysed 34 kindreds with HOOD nephropathy from published reports, comprising 213 patients. For a patient with HOOD from a family in which HOOD nephropathy occurs, the risk of having a child with HOOD nephropathy is about 1:4; the risk of having a child in whom renal failure will develop is about 1:10.
Hereditary osteo-onychodysplasia (HOOD), also known as nail-patella syndrome, is an autosomal dominant hereditary disease. The gene locus is assigned to the distal end of the long arm of chromosome 9,1 linked to the ABO blood group locus, 2 3 with an estimated recombination rate of 10 to 15%. 4 Nail dysplasia and patellar hypoplasia or aplasia are essential features for the diagnosis. Other diagnostic signs are arthrodysplasia of the elbows, leading to increased carrying angle and limited supination and extension, and iliac horns, which are pathognomonic but reported to be present in only 70% of cases.5 Numerous other skeletal abnormalities have been described in patients with HOOD, but either the incidence of each of them is low or they are easily overlooked 18 14, 31,6 25 13, and 2937 years, respectively. In our patient's family this has not yet occurred.
Discussion
Combining the data from our patient's family with those from published reports, we found that nephropathy occurred in 114/236 (48%) and renal failure in 33/239 (14%) of patients with HOOD. Similarly, nephropathy occurred in 62 to 72 (47 to 59%) of 118 to 131 children with HOOD from HOOD/NP+ parents, and renal failure occurred in 6/40 (15%) of HOOD children from parents with HOOD and renal failure, so that neither nephropathy nor renal failure in the parent seems to increase significantly the risk of the same condition in the child. As HOOD is a regular autosomal dominant condition, for a parent with HOOD from a HOOD/NP+ family, the risk of having a child who will develop nephropathy is calculated at 24%, and the risk of having a child in whom renal failure will occur at 7%. However, these figures should be used with caution, as there are four sources of bias.
(1) INTERPRETATION OF PUBLISHED REPORTS Earlier reviews contain cases from HOOD/NPfamilies, leAding to an underestimate of the risk of nephropathy. Why nephropathy occurs in some kindreds but not in others is unknown. Some think it is the result of differences in expression (and the report by Silverman et all' may support such a view), but it could just as well result from different alleles. Therefore, HOOD/NP-kindreds were excluded from the present study. This explains our finding of a considerably higher prevalence of nephropathy among patients with HOOD (48%) than the 30% reported by Simila et al. 8 Recalculation after exclusion of HOOD/NP-families from their material yields a prevalence of 53/116 (46%). Carbonara and Alpert7 found a frequency of proteinuria of 12/29 (41%) in their review, but they may also have included data from HOOD/NP-families. Our own estimate is conservative in assuming that 44 subjects who were not examined did not have nephropathy; if this proved to be incorrect, the frequency could maximally increase to 158/236 (67%).
(2) SELECTION OF CASES REPORTED Kindreds in which nephropathy was not noteworthy, either in frequency or clinical significance, may not be reported or may even go unrecognised, so that published reports may be biased towards the more severely affected families. We have noted large differences in the prevalence of nephropathy among the HOOD/NP+ families reported: the proportion of patients with HOOD that also had nephropathy ranged from 11 to 100%. The smaller families published tend to have more HOOD/NP+ members relative to the number of HOOD/NP-members. We doubt if the large differences in prevalence are merely the result of differences in the extent to which the kindreds were examined or due to sampling. The observed frequency of HOOD in children of HOOD/NP+ parents from published reports, which was about 60% instead of 50%, supports our supposition that selection has also influenced the observed frequency of HOOD nephropathy among children of HOOD/NP+ parents, which was about 27% instead of 24% as would be predicted from the overall prevalence of nephropathy (48%) among HOOD patients. However, we cannot rule out the possibility that nephropathy in a parent increases the risk of nephropathy in a child. ( 
3) AGE OF THE PATIENTS STUDIED
Some patients with HOOD from HOOD/NP+ families will develop clinically detectable nephropathy only after the study. As no preferential age of onset of the nephropathy is apparent, this applies especially to the younger members of a family. This leads to an underestimate of the risk of nephropathy, as may well have occurred in the family of our patient, in which seven of the nine members with HOOD in the fifth generation are less than 11 years of age at present. Omitting this last generation would increase the frequency of nephropathy among family members with HOOD from 43 to 71% (10/14) . The only way to circumvent this problem is to follow up kindreds described earlier, as was done by Schroder,'6 who provided valuable additional information on the kindred described by Kieser, 15 and by Darlington and Hawkins,18 who provided some extra data on the kindred described by Hawkins and Smith. 17 In fact, Kieser'5 found nephropathy in 7/10 HOOD members of the kindred he described, while Schroder found it in 13/15 HOOD members of the same kindred, thus raising the frequency of nephropathy from 70 to 87%. However, this type of study is rarely feasible, as other publications in this category could not be found. Today, the most promising approach to this problem would be centralised electronic storage of files, with regular follow up enquiries entered automatically. The subgroup on which the data are most pertinent to genetic counselling, that is, the children of those HOOD/NP+ patients who develop renal failure, is only small. There are two reasons for this: the incidence of renal failure in patients with HOOD is not high, and until recently, procreation after development of renal failure was virtually impossible. With the introduction of the various forms of renal function replacement therapy, the prognosis of HOOD patients with end stage renal failure has improved dramatically, and since procreation is possible after successful renal transplantation, the demand for genetic counselling is expected to increase, especially in this group of patients.
